{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:23:21Z","timestamp":1791242601612,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Society for Science and Promotion of Science","award":["No.15K19410"],"award-info":[{"award-number":["No.15K19410"]}]},{"name":"Japan Society for Science and Promotion of Science","award":["No. 18K08137"],"award-info":[{"award-number":["No. 18K08137"]}]},{"name":"GSK Japan Research Grant 2017"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.<\/jats:p>","DOI":"10.1038\/s41598-022-08388-6","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T16:05:45Z","timestamp":1647273945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Urine autotaxin levels reflect the disease activity of sarcoidosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Koji","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"8388_CR1","first-page":"149","volume":"16","author":"GW Hunninghake","year":"1999","unstructured":"Hunninghake, G. W. et al. ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis. Vasc. Diffuse Lung Dis. 16, 149\u2013173 (1999).","journal-title":"Sarcoidosis. Vasc. Diffuse Lung Dis."},{"key":"8388_CR2","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi, M. C., Rybicki, B. A. & Teirstein, A. S. Sarcoidosis. N. Engl. J. Med. 357, 2153\u20132165. https:\/\/doi.org\/10.1056\/NEJMra071714 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"565\u2013574","key":"8388_CR3","doi-asserted-by":"publisher","first-page":"x","DOI":"10.1016\/j.ccm.2008.03.006","volume":"29","author":"S Nagai","year":"2008","unstructured":"Nagai, S. et al. Outcome of sarcoidosis. Clin. Chest Med. 29(565\u2013574), x. https:\/\/doi.org\/10.1016\/j.ccm.2008.03.006 (2008).","journal-title":"Clin. Chest Med."},{"key":"8388_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jama.2011.10","volume":"305","author":"MC Iannuzzi","year":"2011","unstructured":"Iannuzzi, M. C. & Fontana, J. R. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 305, 391\u2013399. https:\/\/doi.org\/10.1001\/jama.2011.10 (2011).","journal-title":"JAMA"},{"key":"8388_CR5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/1744666X.2016.1196135","volume":"12","author":"A Chopra","year":"2016","unstructured":"Chopra, A., Kalkanis, A. & Judson, M. A. Biomarkers in sarcoidosis. Expert. Rev. Clin. Immunol. 12, 1191\u20131208. https:\/\/doi.org\/10.1080\/1744666X.2016.1196135 (2016).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"8388_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2183\/pjab.94.025","volume":"94","author":"Y Yatomi","year":"2018","unstructured":"Yatomi, Y. et al. Lysophospholipids in laboratory medicine. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 94, 373\u2013389. https:\/\/doi.org\/10.2183\/pjab.94.025 (2018).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"8388_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jb\/mvu077","volume":"157","author":"S Aikawa","year":"2015","unstructured":"Aikawa, S., Hashimoto, T., Kano, K. & Aoki, J. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J. Biochem. 157, 81\u201389. https:\/\/doi.org\/10.1093\/jb\/mvu077 (2015).","journal-title":"J. Biochem."},{"key":"8388_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pr.110.003111","volume":"62","author":"J Chun","year":"2010","unstructured":"Chun, J., Hla, T., Lynch, K. R., Spiegel, S. & Moolenaar, W. H. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62, 579\u2013587. https:\/\/doi.org\/10.1124\/pr.110.003111 (2010).","journal-title":"Pharmacol. Rev."},{"key":"8388_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1083\/jcb.135.4.1071","volume":"135","author":"JH Hecht","year":"1996","unstructured":"Hecht, J. H., Weiner, J. A., Post, S. R. & Chun, J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135, 1071\u20131083. https:\/\/doi.org\/10.1083\/jcb.135.4.1071 (1996).","journal-title":"J. Cell Biol."},{"key":"8388_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","volume":"1781","author":"J Aoki","year":"2008","unstructured":"Aoki, J., Inoue, A. & Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781, 513\u2013518. https:\/\/doi.org\/10.1016\/j.bbalip.2008.06.005 (2008).","journal-title":"Biochim Biophys Acta"},{"key":"8388_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev.pharmtox.010909.105753","volume":"50","author":"JW Choi","year":"2010","unstructured":"Choi, J. W. et al. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157\u2013186. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105753 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"Suppl","key":"8388_CR12","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1194\/jlr.R800047-JLR200","volume":"50","author":"A Skoura","year":"2009","unstructured":"Skoura, A. & Hla, T. Lysophospholipid receptors in vertebrate development, physiology, and pathology. J. Lipid Res. 50(Suppl), S293-298. https:\/\/doi.org\/10.1194\/jlr.R800047-JLR200 (2009).","journal-title":"J. Lipid Res."},{"key":"8388_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1083\/jcb.200204026","volume":"158","author":"M Umezu-Goto","year":"2002","unstructured":"Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227\u2013233. https:\/\/doi.org\/10.1083\/jcb.200204026 (2002).","journal-title":"J. Cell Biol."},{"key":"8388_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102327","volume":"104","author":"C Magkrioti","year":"2019","unstructured":"Magkrioti, C. et al. Autotaxin and chronic inflammatory diseases. J. Autoimmun. 104, 102327. https:\/\/doi.org\/10.1016\/j.jaut.2019.102327 (2019).","journal-title":"J. Autoimmun."},{"key":"8388_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cca.2011.03.014","volume":"412","author":"H Nakagawa","year":"2011","unstructured":"Nakagawa, H. et al. Autotaxin as a novel serum marker of liver fibrosis. Clin. Chim. Acta 412, 1201\u20131206. https:\/\/doi.org\/10.1016\/j.cca.2011.03.014 (2011).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fmed.2018.00180","volume":"5","author":"I Ninou","year":"2018","unstructured":"Ninou, I., Magkrioti, C. & Aidinis, V. Autotaxin in pathophysiology and pulmonary fibrosis. Front. Med. (Lausanne) 5, 180. https:\/\/doi.org\/10.3389\/fmed.2018.00180 (2018).","journal-title":"Front. Med. (Lausanne)"},{"key":"8388_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.201306-1014OC","volume":"188","author":"GY Park","year":"2013","unstructured":"Park, G. Y. et al. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am. J. Respir. Crit. Care Med. 188, 928\u2013940. https:\/\/doi.org\/10.1164\/rccm.201306-1014OC (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"8388_CR18","doi-asserted-by":"publisher","first-page":"9173090","DOI":"10.1155\/2017\/9173090","volume":"2017","author":"SA Valdes-Rives","year":"2017","unstructured":"Valdes-Rives, S. A. & Gonzalez-Arenas, A. Autotaxin-lysophosphatidic acid: From inflammation to cancer development. Mediators Inflamm. 2017, 9173090. https:\/\/doi.org\/10.1155\/2017\/9173090 (2017).","journal-title":"Mediators Inflamm."},{"key":"8388_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ni1573","volume":"9","author":"H Kanda","year":"2008","unstructured":"Kanda, H. et al. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 9, 415\u2013423. https:\/\/doi.org\/10.1038\/ni1573 (2008).","journal-title":"Nat. Immunol."},{"key":"8388_CR20","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.4049\/jimmunol.1201604","volume":"189","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y., Chen, Y. C., Krummel, M. F. & Rosen, S. D. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J. Immunol. 189, 3914\u20133924. https:\/\/doi.org\/10.4049\/jimmunol.1201604 (2012).","journal-title":"J. Immunol."},{"key":"8388_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1084\/jem.20112012","volume":"209","author":"I Nikitopoulou","year":"2012","unstructured":"Nikitopoulou, I. et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925\u2013933. https:\/\/doi.org\/10.1084\/jem.20112012 (2012).","journal-title":"J. Exp. Med."},{"key":"8388_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14031","author":"Y Iwata","year":"2020","unstructured":"Iwata, Y. et al. Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A1 in patients with lupus nephritis. Int. J. Rheum. Dis. https:\/\/doi.org\/10.1111\/1756-185X.14031 (2020).","journal-title":"Int. J. Rheum. Dis."},{"key":"8388_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/1346-8138.14278","volume":"45","author":"M Kurano","year":"2018","unstructured":"Kurano, M. et al. Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma. J. Dermatol. 45, 571\u2013579. https:\/\/doi.org\/10.1111\/1346-8138.14278 (2018).","journal-title":"J. Dermatol."},{"key":"8388_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2020.01.011","volume":"503","author":"K Nakawatari","year":"2020","unstructured":"Nakawatari, K. et al. Elevated phosphatidylserine-specific phospholipase A1 level in hyperthyroidism. Clin. Chim. Acta 503, 99\u2013106. https:\/\/doi.org\/10.1016\/j.cca.2020.01.011 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR25","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/1756-185X.13689","volume":"22","author":"T Sawada","year":"2019","unstructured":"Sawada, T. et al. Serum phosphatidylserine-specific phospholipase A1 as a novel biomarker for monitoring systemic lupus erythematosus disease activity. Int. J. Rheum. Dis. 22, 2059\u20132066. https:\/\/doi.org\/10.1111\/1756-185X.13689 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"8388_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-5793(93)81724-e","volume":"316","author":"F Bellini","year":"1993","unstructured":"Bellini, F. & Bruni, A. Role of a serum phospholipase A1 in the phosphatidylserine-induced T cell inhibition. Febs. Lett. 316, 1\u20134. https:\/\/doi.org\/10.1016\/0014-5793(93)81724-e (1993).","journal-title":"Febs. Lett."},{"key":"8388_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1258\/acb.2008.007242","volume":"45","author":"S Hosogaya","year":"2008","unstructured":"Hosogaya, S. et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann. Clin. Biochem. 45, 364\u2013368. https:\/\/doi.org\/10.1258\/acb.2008.007242 (2008).","journal-title":"Ann. Clin. Biochem."},{"key":"8388_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2007.10.005","volume":"388","author":"K Nakamura","year":"2008","unstructured":"Nakamura, K. et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin. Chim. Acta 388, 51\u201358. https:\/\/doi.org\/10.1016\/j.cca.2007.10.005 (2008).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1183\/09031936.00075307","volume":"31","author":"T Morimoto","year":"2008","unstructured":"Morimoto, T. et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 31, 372\u2013379. https:\/\/doi.org\/10.1183\/09031936.00075307 (2008).","journal-title":"Eur Respir J"},{"key":"8388_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2169\/internalmedicine.5441-20","volume":"60","author":"T Tamada","year":"2021","unstructured":"Tamada, T. et al. The clinical features of patients with sarcoidosis and malignant diseases in Japan. Intern. Med. 60, 209\u2013216. https:\/\/doi.org\/10.2169\/internalmedicine.5441-20 (2021).","journal-title":"Intern. Med."},{"key":"8388_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1194\/jlr.M014985","volume":"52","author":"R Dusaulcy","year":"2011","unstructured":"Dusaulcy, R. et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 52, 1247\u20131255. https:\/\/doi.org\/10.1194\/jlr.M014985 (2011).","journal-title":"J. Lipid Res."},{"key":"8388_CR32","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1681\/ASN.2017010107","volume":"28","author":"MZ Zhang","year":"2017","unstructured":"Zhang, M. Z. et al. Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a type 2 diabetic model. J. Am. Soc. Nephrol. 28, 3300\u20133311. https:\/\/doi.org\/10.1681\/ASN.2017010107 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"8388_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cca.2020.06.019","volume":"509","author":"Y Morita","year":"2020","unstructured":"Morita, Y. et al. Urinary autotaxin concentrations are associated with kidney injury. Clin. Chim. Acta 509, 156\u2013165. https:\/\/doi.org\/10.1016\/j.cca.2020.06.019 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cca.2012.10.003","volume":"415","author":"H Sumida","year":"2013","unstructured":"Sumida, H. et al. Decrease in circulating autotaxin by oral administration of prednisolone. Clin. Chim. Acta 415, 74\u201380. https:\/\/doi.org\/10.1016\/j.cca.2012.10.003 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2478\/v10039-008-0014-z","volume":"53","author":"E Danila","year":"2008","unstructured":"Danila, E., Jurgauskiene, L. & Malickaite, R. BAL fluid cells and pulmonary function in different radiographic stages of newly diagnosed sarcoidosis. Adv. Med. Sci. 53, 228\u2013233. https:\/\/doi.org\/10.2478\/v10039-008-0014-z (2008).","journal-title":"Adv. Med. Sci."},{"key":"8388_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00011-012-0585-9","volume":"62","author":"G Paone","year":"2013","unstructured":"Paone, G. et al. Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers. Inflamm. Res. 62, 325\u2013332. https:\/\/doi.org\/10.1007\/s00011-012-0585-9 (2013).","journal-title":"Inflamm. Res."},{"key":"8388_CR37","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","volume":"267","author":"ML Stracke","year":"1992","unstructured":"Stracke, M. L. et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524\u20132529 (1992).","journal-title":"J. Biol. Chem."},{"key":"8388_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cca.2009.04.025","volume":"405","author":"K Nakamura","year":"2009","unstructured":"Nakamura, K. et al. Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clin. Chim. Acta 405, 160\u2013162. https:\/\/doi.org\/10.1016\/j.cca.2009.04.025 (2009).","journal-title":"Clin. Chim. Acta"},{"key":"8388_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.plipres.2015.02.001","volume":"58","author":"E Barbayianni","year":"2015","unstructured":"Barbayianni, E., Kaffe, E., Aidinis, V. & Kokotos, G. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Prog. Lipid Res. 58, 76\u201396. https:\/\/doi.org\/10.1016\/j.plipres.2015.02.001 (2015).","journal-title":"Prog. Lipid Res."},{"key":"8388_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.clnu.2009.12.011","volume":"29","author":"S Meeuwsen","year":"2010","unstructured":"Meeuwsen, S., Horgan, G. W. & Elia, M. The relationship between BMI and percent body fat, measured by bioelectrical impedance, in a large adult sample is curvilinear and influenced by age and sex. Clin. Nutr. 29, 560\u2013566. https:\/\/doi.org\/10.1016\/j.clnu.2009.12.011 (2010).","journal-title":"Clin. Nutr."},{"key":"8388_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1164\/rccm.202002-0251ST","volume":"201","author":"ED Crouser","year":"2020","unstructured":"Crouser, E. D. et al. Diagnosis and detection of sarcoidosis: An official American thoracic society clinical practice guideline. Am. J. Respir. Crit. Care Med. 201, 26\u201351. https:\/\/doi.org\/10.1164\/rccm.202002-0251ST (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"8388_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.17-22807","volume":"59","author":"M Honjo","year":"2018","unstructured":"Honjo, M. et al. Role of the autotaxin-LPA pathway in dexamethasone-induced fibrotic responses and extracellular matrix production in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 59, 21\u201330. https:\/\/doi.org\/10.1167\/iovs.17-22807 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8388_CR43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cca.2010.04.006","volume":"411","author":"K Nakamura","year":"2010","unstructured":"Nakamura, K. et al. A novel enzyme immunoassay for the determination of phosphatidylserine-specific phospholipase A(1) in human serum samples. Clin. Chim. Acta 411, 1090\u20131094. https:\/\/doi.org\/10.1016\/j.cca.2010.04.006 (2010).","journal-title":"Clin. Chim. Acta"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08388-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:06:13Z","timestamp":1669334773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08388-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8388"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08388-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4372"}}